[go: up one dir, main page]

WO2016086000A1 - Combinaison de géranylgéranylacétone, d'ibudilast et de riluzole, et leurs procédés d'utilisation - Google Patents

Combinaison de géranylgéranylacétone, d'ibudilast et de riluzole, et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2016086000A1
WO2016086000A1 PCT/US2015/062459 US2015062459W WO2016086000A1 WO 2016086000 A1 WO2016086000 A1 WO 2016086000A1 US 2015062459 W US2015062459 W US 2015062459W WO 2016086000 A1 WO2016086000 A1 WO 2016086000A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
pharmaceutically acceptable
progressive
acceptable salt
riluzole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/062459
Other languages
English (en)
Inventor
Kazuko Matsuda
Yuichi Iwaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of WO2016086000A1 publication Critical patent/WO2016086000A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Definitions

  • the present disclosure relates generally to methods for treating neurodegenerative diseases, including those which are of the progressive variety.
  • the present disclosure pertains to methods of treating or preventing progressive neurodegenerative diseases and its associated symptoms by administration of a combination of geranylgeranylacetone (teprenone), ibudilast (3-isobutyryl-2-isopropylpyrazolo[l,5- ajpyridine), and riluzole (2-amino-6-(trifluoromethoxy) benzothiazole).
  • Ibudilast is a small molecule drug (molecular weight of 230.3) having the structure shown below.
  • Ibudilast is also found under ChemBank ID 3227, CAS # 50847-11-5, and Beilstein Handbook Reference No. 5-24-03-00396. Its molecular formula corresponds to C14H18N2O. Ibudilast is also known by various chemical names including 2-methyl-l-(2-(l- methylethyl)pyrazolo( 1 ,5 -a)pyridin-3 -yl) 1 -propanone; 3 -isobutyryl-2-isopropylpyrazolo (1,5- a)pyridine]; and l-(2-isopropyl-pyrazolo[l,5-a]pyridin-3-yl)-2-methyl-propan-l-one.
  • Ibudilast examples include Ibudilastum (Latin), BR 0656579, KC-404, and MN-166. Its brand name is Ketas R TM. Ibudilast, as referred to herein, is meant to include any and all pharmaceutically acceptable salt forms thereof, prodrug forms (e.g., the corresponding ketal), solvates, and the like, as appropriate for use in its intended formulation for administration.
  • Ibudilast has been widely used in Japan for relieving symptoms associated with ischemic stroke or bronchial asthma.
  • Marketed indications for ibudilast in Japan include its use as a vasodilator, for treating allergy, eye tissue regeneration, ocular disease, and treatment of allergic ophthalmic disease (Thompson Current Drug Reports).
  • US Patent Application Publication No. 2009/0062330 discloses the treatment of progressive neurodegenerative diseases by the administration of ibudilast. This publication generally discloses that ibudilast may be administered in a combination treatment along with an additional agent effective for treating progressive neurodegenerative diseases, but does not provide any guidance on the choice of the additional agent.
  • Geranylgeranyl acetone has the formula: and is marketed as an antiulcer agent in Japan. GGA, alternatively known as teprenone, is also reported to have neuroprotective and related effects. See, for example, PCT Pat. App. Pub. Nos. WO 2012/031028, WO 2013/052148, and WO 2013/130654, each of which is incorporated herein by reference in its entirety. It has also been reported that GGA is an inducer of heat shock protein 70 (HSP70) in mice subjected to an occlusion of the middle cerebral artery. Riluzole
  • HSP70 heat shock protein 70
  • Riluzole has the formula: and is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS).
  • the present disclosure relates to a novel approach to treating a neurodegenerative disease or disorder, including progressive forms, and is based on the administration of a combination of ibudilast, geranylgeranylacetone, and riluzole.
  • the present disclosure is a method of alleviating negative effects of a neurodegenerative disease or disorder in a human patient suffering therefrom, comprising administering to the human patient in need thereof:
  • the disclosure is a method of slowing progression of disease in a patient diagnosed with a chronic neurodegenerative disease, comprising administering to the patient:
  • the disclosure is a method of treating a patient diagnosed with a neurodegenerative disease or disorder, comprising administering to the patient:
  • the neurodegenerative disease or disorder is Alzheimer's disease, Senile dementia of the Alzheimer type, Pick's disease (lobar atrophy), syndromes combining progressive dementia with other prominent neurologic abnormalities, Huntington's disease, multiple system atrophy combining dementia with ataxia and/or manifestation of Parkinson's disease, progressive supranuclear palsy (Steele -Richardson- Olszewski), diffuse Lewy body disease, corticodentatinigral degeneration, Hallervorden- Spatz disease, progressive familial myoclonic epilepsy, symptoms of gradually developing abnormalities of posture and movement, paralysis agitans (Parkinson's disease), striatonigral degeneration, progressive supranuclear palsy, torsion dystonia (torsion spasm; dystonia musculorum deformans), spasmodic torticollis and other restricted dyskinesias, Familial tremor, Gilles de la Tourette syndrome, progressive ataxia, cerebellar degeneration
  • the neurodegenerative disease is of the progressive type.
  • the neurodegenerative disease or disorder is Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis.
  • the neurodegenerative disease or disorder is ALS.
  • the disclosure is a method of reducing a volume of an infarct (an area of necrosis in a tissue or organ resulting from obstruction of the local circulation by a thrombus or embolus) in a patient suffering from an ischemia, comprising administering to a patient in need thereof:
  • the ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof are administered orally.
  • the three active ingredients mentioned above may be administered together, separately and, if separately, each may be administered at the same time or at different time intervals.
  • ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof are administered in separate dosage forms.
  • the ibudilast or pharmaceutically acceptable salt thereof, the GGA or a pharmaceutically acceptable salt thereof, and the riluzole or pharmaceutically acceptable salt thereof are administered in the same dosage form.
  • the ibudilast or a pharmaceutically acceptable salt thereof is administered in an amount from about 100 to about 4,000 mg/day, divided into one, two, or three portions.
  • the GGA or pharmaceutically acceptable salt thereof is administered in an amount from about 1 mg/kg to about 1000 mg/kg of the patient.
  • the riluzole or pharmaceutically acceptable salt thereof is administered in an amount from about 1 mg/kg to about 1000 mg/kg of the patient, divided into one, two, or three portions.
  • the riluzole or pharmaceutically acceptable salt thereof is administered at a total dose of from about 10 mg per day to about 500 mg per day.
  • the riluzole or pharmaceutically acceptable salt thereof is administered once a day at a dose of from about 10 mg to about 500 mg. In another embodiment, the riluzole or pharmaceutically acceptable salt thereof is administered twice a day at a total dose of from about 10 mg per day to about 500 mg per day.
  • composition for oral administration comprising:
  • the composition comprises from about 100 to about 4,000 mg of ibudilast or a pharmaceutically acceptable salt thereof, from about 50 mg to about 4,000 mg of GGA or a pharmaceutically acceptable salt thereof, and from about 10 to about 500 mg/day of riluzole or a pharmaceutically acceptable salt thereof.
  • the composition is an oral tablet or capsule. In another embodiment, the composition is an oral liquid dosage form.
  • FIG.l graphically illustrates comparative life span in Sodl mutants (Sodl ) and wt (Sodl +). Maximum life span of mutants is 25-30 days compared to 70-80 days for controls; recovering on life span curve can indicate positive compound activity.
  • FIG.2 graphically illustrates high (% viability) sensitivity of SOD 1 -null adults compared to a wild stock after exposition of adult flies to 2 mmol of paraquat. Resistance to paraquat treatment can indicate positive activity of the compound tested.
  • administering or "administration of a drug to a patient (and grammatical equivalents of this phrase) includes both direct administration, including self-administration, and indirect administration, including the act of prescribing a drug.
  • direct administration including self-administration
  • indirect administration including the act of prescribing a drug.
  • a physician who instructs a patient to self-administer a drug and/or provides a patient with a prescription for a drug is administering the drug to the patient.
  • compositions shall mean that the methods and compositions include the recited elements, but not exclude others.
  • Consisting essentially of when used to define methods and compositions shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives and the like.
  • Consisting of shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this disclosure or process steps to produce a composition or achieve an intended result. Embodiments defined by each of these transitional terms and phrases are within the scope of this disclosure.
  • Effective amount of a compound utilized herein is an amount that, when administered to a patient treated as herein, will have the intended therapeutic effect, e.g., alleviation, amelioration, palliation or elimination of one or more manifestations of the medical condition in the patient.
  • the full therapeutic effect does not necessarily occur by administration of one dose (or dosage), and may occur only after administration of a series of doses. Thus, an effective amount may be administered in one or more administrations.
  • “Pharmaceutically acceptable” refers to non-toxic and suitable for administration to a patient, including a human patient.
  • “Pharmaceutically acceptable salts” refer to salts that are non-toxic and are suitable for administration to patients.
  • “Pharmaceutically acceptable salt” includes, but is not limited to, amino acid salts, salts prepared with inorganic acids, such as chloride, sulfate, phosphate, diphosphate, bromide, and nitrate salts, or salts prepared from the corresponding inorganic acid form of any of the preceding, e.g., hydrochloride, etc., or salts prepared with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, ethylsuccinate, citrate, acetate, lactate, methanesulfonate, benzoate, ascorbate, para-toluenesulfonate, palmoate, salicylate and stearate, as well as estolate, gluceptate and lactobionate salts.
  • salts containing pharmaceutically acceptable cations include, but are not limited
  • Treating" a medical condition or a patient refers to taking steps to obtain beneficial or desired results, including clinical results.
  • beneficial or desired clinical results include, but are not limited to, reduction, alleviation, or amelioration of one or more manifestations of or negative effects of ALS, PLS or familial ALS, improvement in one or more clinical outcomes, diminishment of extent of sclerosis, delay or slowing of sclerosis progression, amelioration, palliation, or stabilization of the scleroses state, and other beneficial results described herein.
  • neurodegenerative disease means any neurodegenerative disease that causes the loss of structure or function of neurons in the nervous system of an individual, including death of neurons.
  • Neurodegenerative disease includes progressive neurodegenerative diseases, in which the symptoms worsen over time. In certain instances, the symptoms worsen at a gradual rate. Examples of progressive neurodegenerative diseases include Alzheimer's Disease, Parkinsonism and amyotrophic lateral sclerosis.
  • An example of a neurodegenerative disease is a relapsing and remitting form of multiple sclerosis (MS). MS also exhibits progressive forms.
  • central nervous system includes all cells and tissue of the brain and spinal cord of a vertebrate. Thus, the term includes, but is not limited to, neuronal cells, glial cells, astrocytes, cerebrospinal fluid (CSF), interstitial spaces and the like.
  • CSF cerebrospinal fluid
  • subject refers to a vertebrate, preferably a mammal.
  • Mammals include, but are not limited to, murines, rodents, simians, humans, farm animals, sport animals and pets.
  • compositions or agents refer to a nontoxic but sufficient amount of the composition or agent to provide the desired response, such as a reduction, alleviation, or reversal of the symptoms of neurodegenerative diseases.
  • amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the particular drug or drugs employed, mode of administration, and the like.
  • An appropriate "effective" amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation, based upon the information provided herein.
  • any one or more of the herein-described drugs, in particular ibudilast is meant to encompass, where applicable, any and all enantiomers, mixtures of enantiomers including racemic mixtures, prodrugs, pharmaceutically acceptable salt forms, hydrates (e.g., monohydrates, dihydrates, etc.), solvates, different physical forms (e.g., crystalline solids, amorphous solids), metabolites, and the like.
  • the GGA used in a composition of the present disclosure is a synthetic 5 -trans isomer compound of formula III: wherein III is at least 80% in the 5E, 9E, 13E configuration.
  • the disclosure utilizes a compound of formula III wherein at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or at least 99.5%, or at least 99.9% is in the 5E, 9E, 13E configuration.
  • the disclosure for the compound of formula III does not contain any of the cis-isomer of GGA.
  • the GGA used in a composition of the present disclosure is a synthetic 5-cis isomer compound of formula IV: wherein IV is at least 75% in the 5Z, 9E, 13E configuration.
  • the disclosure utilizes a compound of formula IV wherein IV is at least 80%> in the 5E, 9E, 13E configuration, or alternatively, at least 85%, or at least 90%>, or at least 95%, or at least 96%>, or at least 97%, or at least 98%, or at least 99%, or at least 99.5%, or at least 99.9% in the 5E, 9E, 13E configuration.
  • the compound of formula VII does not contain any of the trans-isomer of GGA.
  • the configuration of compounds can be determined by methods known to those skilled in the art such as chiroptical spectroscopy and nuclear magnetic resonance spectroscopy.
  • the disclosure is a method of alleviating negative effects of a neurodegenerative disease or disorder in a human patient suffering therefrom, comprising administering to a patient in need thereof:
  • the disclosure is a method of slowing progression of disease in a patient diagnosed with a chronic neurodegenerative disease, comprising administering to the patient: (a) a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof,
  • the disclosure is a method of treating a patient diagnosed with a neurodegenerative disease or disorder, comprising administering to the patient:
  • the neurodegenerative disease or disorder compromises the nervous system.
  • the neurodegenerative disease or disorder is Alzheimer's disease, Senile dementia of the Alzheimer type, Pick's disease (lobar atrophy), syndromes combining progressive dementia with other prominent neurologic abnormalities, Huntington's disease, multiple system atrophy combining dementia with ataxia and/or manifestation of Parkinson's disease, progressive supranuclear palsy (Steele -Richardson- Olszewski), diffuse Lewy body disease, corticodentatinigral degeneration, Hallervorden- Spatz disease, progressive familial myoclonic epilepsy, symptoms of gradually developing abnormalities of posture and movement, paralysis agitans (Parkinson's disease), striatonigral degeneration, progressive supranuclear palsy, torsion dystonia (torsion spasm; dystonia musculorum deformans), spasmodic torticollis and other restricted dyskinesias, Familial tremor, Gilles de la Tourette syndrome, progressive ataxia, cerebellar degeneration
  • the neurodegenerative disease or disorder is Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis. In a particular embodiment, the neurodegenerative disease or disorder is ALS.
  • the disclosure is a method of reducing a volume of an infarct (an area of necrosis in a tissue or organ resulting from obstruction of the local circulation by a thrombus or embolus) in a patient suffering from an ischemia, comprising administering to a patient in need thereof:
  • the present disclosure comprises administering ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, either systemically or centrally (e.g., by intrathecal administration, i.e., into the cerebrospinal fluid surrounding the spinal cord).
  • the present disclosure comprises administering ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, systemically, e.g., via parenteral, enteral, oral, intravenous, intranasal, sublingual or other systemic routes, to a human, subject for the treatment of progressive neurodegenerative diseases.
  • the present disclosure comprises administering ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, orally.
  • the disclosure comprises administering ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, as a single combination composition.
  • the disclosure comprises administering ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, as separate dosage forms.
  • ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, and are administered as separate dosage forms and co-administration is required, ibudilast, geranylgeranylacetone, and riluzole may be administered simultaneously, sequentially in any order, or separately.
  • the disclosure is a composition, comprising:
  • composition comprising:
  • composition comprising:
  • composition is effective to alleviate the negative effects of a neurodegenerative disease or disorder in a human patient suffering therefrom.
  • Effective dosage levels of ibudilast can vary from about 100 to about 4000 mg per day. In one embodiment, the daily dosage range is 250 to 2,000 mg, given in one, two, or three portions. In one embodiment, the daily dosage range of ibudilast is 100 to 500 mg, such as 100, 200, 300, 400, or 500 mg given in one, two, or three portions. In one embodiment, the daily dosage range of ibudilast is about 250 to about 2,000 mg, such as 250, 500, 750, 1,000, 1,250, 1,500, 1,750, or 2,000 mg given in one, two, or three portions.
  • the daily dosage range of ibudilast is from about 1000 to about 4,000 mg, such as about 1,000, about 2,000, about 3,000, or about 4,000 mg, given in one, two, or three portions.
  • the dosage is about 1000 mg twice a day.
  • suitable dosages of ibudilast include about 1000 mg four times a day, about 1000 mg twice a day, and about 750 mg three times a day.
  • An effective dose of GGA in a composition of the present disclosure is from about 0.1 mg/kg/day to about 4,000 mg/kg/day, or from about 1 mg/kg/day to about 50 mg/kg/day, or from about 1 mg/kg/day to about 25 mg per kg/day.
  • the effective amount of riluzole is from about 1 mg/kg/day to about 1000 mg/kg/day given in one, two, or three portions. In some other embodiments, the effective amount of GGA is from about 10 mg/kg/day to about 100 mg/kg/day, about 20 mg/kg/day to about 90 mg/kg/day, about 30 mg/kg/day to about 80 mg/kg/day, about 40 mg/kg/day to about 70 mg/kg/day, or about 50 mg/kg/day to about 60 mg/kg/day. In still some other embodiments, the dose of GGA is from about 100 mg/kg/day to about 1000 mg/kg/day. In some embodiments, the daily dose of riluzole is given in one, two, or three portions.
  • An effective dose of riluzole in a composition of the present disclosure is from about 0.1 mg/kg/day to about 4,000 mg/kg/day, or from about 1 mg/kg/day to about 50 mg/kg/day, or from about 1 mg/kg/day to about 25 mg per kg/day.
  • the effective amount of riluzole is from about 10 mg/kg/day to about 100 mg/kg/day, about 20 mg/kg/day to about 90 mg/kg/day, about 30 mg/kg/day to about 80 mg/kg/day, about 40 mg/kg/day to about 70 mg/kg/day, or about 50 mg/kg/day to about 60 mg/kg/day.
  • the dose of riluzole is from about 100 mg/kg/day to about 1000 mg/kg/day. In particular embodiments, the total dose of riluzole about 10 mg/day to about 500 mg/day.
  • compositions according to the present disclosure will ordinarily be formulated with one or more pharmaceutically acceptable ingredients in accordance with known and established practice.
  • tablets are formed utilizing a carrier such as modified starch, alone or in combination with carboxymethyl cellulose (Avicel), for example at about 10% by weight.
  • the formulations are compressed at from 1,000 to 3,000 pounds pressure in the tablet forming process.
  • the tablets preferably exhibit an average hardness of about 1.5 to 8.0 kp/cm 2 , preferably 5.0 to 7.5 kp/cm 2 .
  • Disintegration time varies from about 30 seconds to about 15 or 20 minutes.
  • compositions for oral use can be provided as hard gelatin capsules wherein the therapeutically active compounds utilized herein are mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the compounds are mixed with an oleaginous medium, e.g., liquid paraffin or olive oil.
  • Suitable carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, and the like.
  • compositions of the present disclosure can be formulated as aqueous suspensions in admixture with pharmaceutically acceptable excipients such as suspending agents including, but not limited to, sodium carboxymethyl cellulose, methylcellulose, hydroxypropylmethyl cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as naturally occurring phosphatide, e.g., lecithin, or condensation products of an alkaline oxide with fatty acids, e.g., polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, e.g, heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol, e.g., polyoxyethylene sorbitol monoleate or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydr
  • Such aqueous suspensions can also contain one or more preservatives, e.g., ethyl- or n-propyl-p-hydroxy benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as glycerol, sorbitol, sucrose, saccharin or sodium or calcium cyclamate.
  • preservatives e.g., ethyl- or n-propyl-p-hydroxy benzoate
  • coloring agents e.g., ethyl- or n-propyl-p-hydroxy benzoate
  • flavoring agents e.g., sorbitol, sucrose, saccharin or sodium or calcium cyclamate.
  • sweetening agents such as glycerol, sorbitol, sucrose, saccharin or sodium or calcium cyclamate.
  • compositions of the present disclosure also include sustained release dosage forms, such as those described in U.S. Pat. Nos. 4,788,055; 4,816,264; 4,828,836; 4,834,965; 4,834,985; 4,996,047; 5,071,646; and, 5,133,974, the contents of which are incorporated herein in their entirety by reference.
  • compositions of the present disclosure suitable for oral administration include liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations.
  • Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents, for example, such as lecithin, sorbitan monooleate, or acacia.
  • Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents.
  • Solid form preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • compositions of the present disclosure may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example as solutions in aqueous polyethylene glycol.
  • oily or nonaqueous carriers, diluents, solvents or vehicles examples include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
  • compositions of the present disclosure can be formulated for nasal administration.
  • the solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray.
  • the formulations may be provided in a single or multidose form.
  • the patient can administer an appropriate, predetermined volume of the solution or suspension via a dropper or pipette.
  • a spray may be administered for example by means of a metering atomizing spray pump.
  • compositions of the present disclosure can be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration.
  • the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
  • the active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC), (for example, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane), carbon dioxide or other suitable gases.
  • CFC chlorofluorocarbon
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • the dose of drug may be controlled by a metered valve.
  • the active ingredients may be provided in a form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine.
  • a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine.
  • the powder carrier will form a gel in the nasal cavity.
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of, for example gelatin or blister packs from which the powder may be administered by means of an inhaler.
  • compositions of the present disclosure may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also containing one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
  • Formulations suitable for topical administration in the mouth include lozenges including active agents in a flavored base, usually sucrose and acacia or tragacanth; pastilles including the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes including the active ingredient in a suitable liquid carrier.
  • compositions of the present disclosure may be formulated for administration as suppositories.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.
  • compositions of the present disclosure may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • compositions of the present disclosure may further comprise one or more pharmaceutically acceptable excipients or carriers.
  • excipients include, without limitation, polyethylene glycol (PEG), hydrogenated castor oil (HCO), cremophors, carbohydrates, starches (e.g., corn starch), inorganic salts, antimicrobial agents, antioxidants, binders/fillers, surfactants, lubricants (e.g., calcium or magnesium stearate), glidants such as talc, disintegrants, diluents, buffers, acids, bases, film coats, combinations thereof, and the like.
  • PEG polyethylene glycol
  • HCO hydrogenated castor oil
  • cremophors carb, starches (e.g., corn starch), inorganic salts, antimicrobial agents, antioxidants, binders/fillers, surfactants, lubricants (e.g., calcium or magnesium stearate), glidants such as talc, disintegrants, diluents,
  • a composition of the disclosure may include one or more carbohydrates such as a sugar, a derivatized sugar such as an alditol, aldonic acid, an esterified sugar, and/or a sugar polymer.
  • Specific carbohydrate excipients include, for example: monosaccharides, such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and the like; polysaccharides, such as raffmose, melezitose, maltodextrins, dextrans, starches, and the like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), pyranosyl sorbitol, myoinositol, and the
  • compositions of the disclosure are potato and corn-based starches such as sodium starch glycolate and directly compressible modified starch.
  • composition of the disclosure may also include an antimicrobial agent, e.g., for preventing or deterring microbial growth.
  • antimicrobial agents suitable for the present disclosure include benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate, thimersol, and combinations thereof.
  • a composition of the disclosure may also contain one or more antioxidants.
  • Antioxidants are used to prevent oxidation, thereby preventing the deterioration of the drug(s) or other components of the preparation.
  • Suitable antioxidants for use in the present disclosure include, for example, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, and combinations thereof.
  • Additional excipients include surfactants such as polysorbates, e.g., "Tween 20" and “Tween 80,” and pluronics such as F68 and F88 (both of which are available from BASF, Mount Olive, N.J.), sorbitan esters, lipids (e.g., phospholipids such as lecithin and other phosphatidylcholines, and phosphatidylethanolamines), fatty acids and fatty esters, steroids such as cholesterol, and chelating agents, such as EDTA, zinc and other such suitable cations.
  • surfactants such as polysorbates, e.g., "Tween 20" and “Tween 80,” and pluronics such as F68 and F88 (both of which are available from BASF, Mount Olive, N.J.), sorbitan esters, lipids (e.g., phospholipids such as lecithin and other phosphatidylcholines, and phosphatidylethanolamines
  • composition of the disclosure may optionally include one or more acids or bases.
  • acids that can be used include those acids selected from the group consisting of hydrochloric acid, acetic acid, phosphoric acid, citric acid, malic acid, lactic acid, formic acid, trichloroacetic acid, nitric acid, perchloric acid, phosphoric acid, sulfuric acid, fumaric acid, and combinations thereof.
  • Suitable bases include, without limitation, bases selected from the group consisting of sodium hydroxide, sodium acetate, ammonium hydroxide, potassium hydroxide, ammonium acetate, potassium acetate, sodium phosphate, potassium phosphate, sodium citrate, sodium formate, sodium sulfate, potassium sulfate, potassium fumerate, and combinations thereof.
  • the amount of any individual excipient in the composition will vary depending on the role of the excipient, the dosage requirements of the active agent components, and particular needs of the composition. Typically, the optimal amount of any individual excipient is determined through routine experimentation, i.e., by preparing compositions containing varying amounts of the excipient (ranging from low to high), examining the stability and other parameters, and then determining the range at which optimal performance is attained with no significant adverse effects.
  • the excipient will be present in the composition in an amount of about 1% to about 99% by weight, preferably from about 5% to about 98%> by weight, more preferably from about 15 to about 95% by weight of the excipient.
  • the amount of excipient present in an ibudilast composition of the disclosure is selected from the following: at least about 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or even 95% by weight.
  • compositions of the present disclosure can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient.
  • a common type of controlled release formulation that may be used for the purposes of the present disclosure comprises an inert core, such as a sugar sphere, a first layer, coated with an inner drug-containing second layer, and an outer membrane or third layer controlling drug release from the inner layer.
  • the cores are preferably of a water-soluble or swellable material, and may be any such material that is conventionally used as cores or any other pharmaceutically acceptable water-soluble or water- swellable material made into beads or pellets.
  • the cores may be spheres of materials such as sucrose/starch (Sugar Spheres NF), sucrose crystals, or extruded and dried spheres typically comprised of excipients such as microcrystalline cellulose and lactose.
  • the substantially water-insoluble material in the first layer is generally a "GI insoluble” or "GI partially insoluble” film forming polymer (dispersed or dissolved in a solvent).
  • GI insoluble or "GI partially insoluble” film forming polymer (dispersed or dissolved in a solvent).
  • ethyl cellulose, cellulose acetate, cellulose acetate butyrate polymethacrylates such as ethyl acrylate/methyl methacrylate copolymer (Eudragit
  • plasticizers include: dibutylsebacate, propylene glycol, triethylcitrate, tributylcitrate, castor oil, acetylated monoglycerides, acetyl triethylcitrate, acetyl butylcitrate, diethyl phthalate, dibutyl phthalate, triacetin, fractionated coconut oil (medium-chain triglycerides).
  • the second layer containing the active ingredient may be comprised of the active ingredient (drug) with or without a polymer as a binder.
  • the binder when used, is usually hydrophilic but may be water-soluble or water-insoluble.
  • Exemplary polymers to be used in the second layer containing the active drug are hydrophilic polymers such as polyvinylpyrrolidone, polyalkylene glycol such as polyethylene glycol, gelatine, polyvinyl alcohol, starch and derivatives thereof, cellulose derivatives, such as hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose, carboxymethyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, carboxyethyl cellulose, carboxymethyl hydroxyethyl cellulose, acrylic acid polymers, polymethacrylates, or any other pharmaceutically acceptable polymer.
  • the ratio of drug to hydrophilic polymer in the second layer is usually in the range of from 1 : 100 to 100: 1 (w/
  • Suitable polymers for use in the third layer, or membrane, for controlling the drug release may be selected from water insoluble polymers or polymers with pH-dependent solubility, such as, for example, ethyl cellulose, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, polymethacrylates, or mixtures thereof, optionally combined with plasticizers, such as those mentioned above.
  • the controlled release layer comprises, in addition to the polymers above, another substance(s) with different solubility characteristics, to adjust the permeability, and thereby the release rate, of the controlled release layer.
  • exemplary polymers that may be used as a modifier together with, for example, ethyl cellulose include: HPMC, hydroxyethyl cellulose, hydroxypropyl cellulose, methylcellulose, carboxymethylcellulose, polyethylene glycol, polyvinylpyrrolidone (PVP), polyvinyl alcohol, polymers with pH-dependent solubility, such as cellulose acetate phthalate or ammonio methacrylate copolymer and methacrylic acid copolymer, or mixtures thereof.
  • Additives such as sucrose, lactose and pharmaceutical grade surfactants may also be included in the controlled release layer, if desired.
  • unit dosage forms of the compositions are subdivided into unit dosages containing appropriate quantities of the active component (e.g., and without limitation, a compound of Formula (I) or an ester thereof, or a salt of each thereof).
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • a formulation (or kit) in accordance with the disclosure may contain, in addition to ibudilast, geranylgeranylacetone, and riluzole, or pharmaceutically acceptable salts thereof, one or more additional active agents effective in treating progressive neurodegenerative diseases.
  • the active agent is one that possesses a mechanism of action different from that of ibudilast, geranylgeranylacetone, and riluzole.
  • Such actives include the combinations for pain listed in US Application No. 20060160843, as well as the active ingredients recognized for treatment for the target diseases. Such active ingredients can be found listed in the FDA's Orange Book, Goodman & Gilman The Pharmacological Basis of Therapeutics, J. Griffith Hardman, L. L. Limbird, A. Gilman, 11th Ed., 2005, The Merck Manual, 18th edition, 2007, and The Merck Manual of Medical Information 2003.
  • compositions of the present disclosure can be evaluated by any of the standard progressive neuropathic disease models known in the art. Examples of such models are described in Animal Models of Neurological Disease: Neurodegenerative Diseases (Neuromethods) by Alan A. Boulton, Glen B. Baker, and Roger F. Butterworth (1992); Handbook of Laboratory Animal Science, Second Edition: Volumes I-III (Handbook of Laboratory Animal Science) by Jann Hau (Editor), Jr., Gerald L. Van Hoosier (Editor). (2004); Animal Models of Movement Disorders by Mark LeDoux (Editor), (2005); and Animal Models of Cognitive Impairment (Frontiers in Neuroscience) (2006) by Edward D. Levin (Editor), Jerry J. Buccafusco (Editor).
  • kits containing at least one combination composition of the disclosure, accompanied by instructions for use.
  • the kit comprises ibudilast, geranylgeranylacetone, and riluzole, or pharmaceutically acceptable salts thereof, along with instructions for use.
  • the ibudilast, geranylgeranylacetone, and riluzole, or pharmaceutically acceptable salts thereof may be packaged in any manner suitable for administration, so long as the packaging, when considered along with the instructions for administration, clearly indicates the manner in which each of the drug components is to be administered.
  • kits comprising ibudilast, geranylgeranylacetone, and riluzole, or pharmaceutically acceptable salts thereof
  • the kit may be organized by any appropriate time period, such as by day.
  • a representative kit may comprise unit dosages of each of ibudilast, geranylgeranylacetone, and riluzole, or pharmaceutically acceptable salts thereof.
  • the kit may contain, corresponding to Day 1 , two rows of unit dosage forms of each of ibudilast, geranylgeranylacetone, and riluzole, or pharmaceutically acceptable salts thereof, along with instructions for the timing of administration.
  • ibudilast, geranylgeranylacetone, and riluzole, or pharmaceutically acceptable salts thereof differ in the timing or quantity of administration, then such would be reflected in the packaging and instructions.
  • Various embodiments according to the above may be readily envisioned, and would of course depend upon the particular combination of drugs, in addition to ibudilast, geranylgeranylacetone, and riluzole, or pharmaceutically acceptable salts thereof, employed for treatment, their corresponding dosage forms, recommended dosages, intended patient population, and the like.
  • the packaging may be in any form commonly employed for the packaging of pharmaceuticals, and may utilize any of a number of features such as different colors, wrapping, tamper-resistant packaging, blister packs, dessicants, and the like.
  • Example 1 Drosophila life span assay as an ALS treatment model
  • Drosophila males will be collected. Flies will be transferred to fresh food (with active compounds) every 2-3 days. Daily, the number of living flies are analyzed. The experiment is performed under temperature controlled conditions (25°C) and uses negative control (only solvent), and positive controls (wt stock, any antioxidant compound reported as able to increase life span in this fly model). In order to compare the activity of the testing compounds with riluzole (an FDA-approved drug for ALS), this drug will be added to the assay.
  • riluzole an FDA-approved drug for ALS
  • the experiment includes the analysis of different compound concentrations of ibudilast, geranylgeranylacetone, and riluzole, each at different concentrations and will evaluate 240 flies for each concentration. Recovering on life span curve can indicate positive compound activity. See, FIG. 1.
  • Example 2 Drosophila paraquat sensitivity assay as an ALS treatment model
  • Drosophila males will be collected and keep on fly food for 24 h. Then flies will be transferred to vials containing 3 -mm paper filter disks saturated with 250 ⁇ of 1% sucrose containing 2 mM paraquat or 1% sucrose, 2 mM paraquat and the tested compounds. The vials will be stored at 25 °C in the dark, and flies are enumerated after 24 h.
  • Vap-33A M48 or Vap-33A A2 ° stocks display neurophysiology defects linked to a lethal phenotype during larvae development. Viability assay
  • Vap-33A A mutants are larval lethal with rare adult escapers ( ⁇ 1%) 7 . Embryos or larvae at stage 1 will be seeded on fly food with different compound concentrations of ibudilast-GGA combinations. Three replicas for each combination will be performed in the same day. Three replicas of the assay will be performed in different days. Number of adult escapers will be quantified after 14 days of compound treatment. A negative control (only solvent), and positive controls (wt stock, any antioxidant compound reported as able to increase life span in this fly model), and riluzole alone will be added to the assay.
  • the experiment includes the analysis of four compound combinations and will evaluate 180 flies for each concentration (4 replicates x 3 days with 15 flies each one).
  • Example 4 Evaluation of ibudilast, geranylgeranylacetone, and riluzole combination in a rat model of Alzheimer's disease
  • a rat animal model for Alzheimer's disease is administered ibudilast, geranylgeranylacetone, and riluzole and an increase brain mass is achieved for the group, thereby indicating that this model can be effective for the treatment of Alzheimer' disease in humans.
  • Example 5 Evaluation of ibudilast, geranylgeranylacetone, and riluzole combination in a rat model of ALS
  • An animal model for ALS is administered ibudilast, geranylgeranylacetone, and riluzoleand an increase brain mass is achieved for the group of animals being administered ibudilast, geranylgeranylacetone, and riluzole, thereby indicating that this model can be effective for the treatment ALS.
  • Example 6 Evaluation of ibudilast, geranylgeranylacetone, and riluzole combination in a rat model of Parkinson's disease
  • An animal model for Parkinson's disease is administered ibudilast, geranylgeranylacetone, and riluzole, and an increase brain mass is achieved for this group, thereby indicating that this model can be effective for the treatment Parkinson's disease.
  • Example 7 Clinical Trial of the ibudilast, geranylgeranylacetone, and riluzole combination to evaluate its effectiveness in Alzheimer's Disease
  • a combination of ibudilast, geranylgeranylacetone, and riluzole is administered to patients exhibiting the symptoms of Alzheimer's disease, as diagnosed by their physician and confirmed by an independent board-certified neurologist.
  • the patients Prior to the clinical trial, the patients undergo appropriate psychoneurological tests such as the Mini Mental Status Exam (MMSE), the Alzheimer Disease Assessment Scale (ADAS), the Boston Naming Test (BNT), and the Token Test (TT). Neuropsychological tests are repeated at appropriate points during the clinical trial. The tests are performed by neuropsychologists who are not aware of the patients' treatment regimen.
  • MMSE Mini Mental Status Exam
  • ADAS Alzheimer Disease Assessment Scale
  • BNT Boston Naming Test
  • TT Token Test
  • test patients are randomly assigned to the test group or placebo group at the beginning of the study.
  • the ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, and placebo are administered orally at pre- designated intervals.
  • the test patients are evaluated for a specified period of time to determine the effectiveness of treatment using the composition as compared to the control group individuals given a placebo. Scores are statistically compared between the test composition and the placebo for each of the three observational periods. Without treatment, the natural course of Alzheimer's disease results in significant deterioration of a patient's test scores during the course of the clinical trial.
  • Example 8 Clinical Trial of the ibudilast, geranylgeranylacetone, and riluzole combination to evaluate its effectiveness in ALS
  • a combination of ibudilast, geranylgeranylacetone, and riluzole, or pharmaceutically acceptable salts thereof, are administered to patients exhibiting the symptoms of ALS.
  • ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, and placebo are administered orally at pre- designated intervals to a patient group and a placebo group.
  • the test patients are evaluated for a specified period of time to determine the effectiveness of treatment using the composition as compared to the control group individuals given a placebo.
  • the TUFTS Quantitative Neuromuscular Examination (TQNE) is a well standardized, reliable, validated test to measure strength and function in ALS.
  • the test involves measurement of maximum voluntary isometric contraction (MVIC) of 8 muscle groups in the arms using a strain gauge tensiometer. This measurement is a standard for clinical trials in ALS.
  • the ALS Functional Rating Scale (ALSFRS) is an rating scale used to determine patients' assessment of their ability and independence in 10 functional activities. Validity has been established by correlating ALSFRS scores with change in strength over time.
  • the ALSFRS is generally a secondary outcome measure in clinical trials. A patient treated with the combination of the disclosure is considered improved if the patient's scores remain the same or improve compared to placebo during the course of the clinical trial.
  • Example 9 Clinical Trial of the ibudilast, geranylgeranylacetone, and riluzole combination to evaluate its effectiveness in Parkinson's Disease
  • a combination of ibudilast, geranylgeranylacetone, and riluzole, or a pharmaceutically acceptable salts thereof, are administered to patients exhibiting the symptoms of Parkinson's disease.
  • ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, and placebo are administered orally at pre- designated intervals to a patient group and a placebo group.
  • the test patients are evaluated for a specified period of time to determine the effectiveness of treatment using the composition as compared to the control group individuals given a placebo.
  • the prespecified primary efficacy outcome for Parkinson's disease is a change in the Activities of Daily Living and Motor components of the generally accepted Unified Parkinson's Disease Rating Scale (UPDRS II/III) between baseline and the last evaluation on treatment.
  • UPDRS II/III Unified Parkinson's Disease Rating Scale
  • Other assessment scales such as the UPDRS component scores (mental, motor, ADL), the modified Hoehn and Yahr Stage, Modified Schwab and England ADL score may be used to evaluate the efficacy of the present disclosure.
  • Example 10 Clinical Trial of the ibudilast, geranylgeranylacetone, and riluzole combination to evaluate its effectiveness in multiple sclerosis
  • a combination of ibudilast, geranylgeranylacetone, and riluzole, or a pharmaceutically acceptable salts thereof, are administered to patients exhibiting the symptoms of multiple sclerosis.
  • the test composition and placebo are administered orally at pre-designated intervals to a patient group and a placebo group.
  • a clinical trial will include multiple sclerosis patients diagnosed on McDonald criteria, with a baseline Expanded Disability Status Scale (EDDS) between 0 and 5 and either at least one relapse within the last 12 months of randomization and a previous MRI scanning showing lesions consistent with multiple sclerosis or Gd E lesions on MRI scan done within 6 months of randomization.
  • EDDS Expanded Disability Status Scale
  • the primary endpoint for the clinical trial is time -to-confirmed disease progression or treatment failure as measured by EDSS or Multiple Sclerosis Functional Composite Score. Secondary endpoints include relapse rate -related endpoints and MRI measurement-related endpoints. Other tertiary endpoints may be measured, including cognitive function-related endpoints and quality of life-related endpoints.
  • a method of alleviating negative effects of a neurodegenerative disease or disorder in a human patient suffering therefrom comprising administering to the human patient in need thereof: (a) a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof,
  • Embodiment 2 The method of Embodiment 1, wherein the ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, are administered in separate dosage forms.
  • Embodiment 3 The method of Embodiment 1, wherein ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, are administered in the same dosage form.
  • the neurodegenerative disease or disorder is Alzheimer's disease, Senile dementia of the Alzheimer type, Pick's disease (lobar atrophy), syndromes combining progressive dementia with other prominent neurologic abnormalities, Huntington's disease, multiple system atrophy combining dementia with ataxia and/or manifestation of Parkinson's disease, progressive supranuclear palsy (Steele-Richardson-Olszewski), diffuse Lewy body disease, corticodentatinigral degeneration, Hallervorden-Spatz disease, progressive familial myoclonic epilepsy, symptoms of gradually developing abnormalities of posture and movement, paralysis agitans (Parkinson's disease), striatonigral degeneration, progressive supranuclear palsy, torsion dystonia (torsion spasm; dystonia musculorum deformans), spasmodic torticollis and other restricted dyskinesias, Familial tremor, Gilles de la Tourette syndrome, progressive at
  • the neurodegenerative disease or disorder is Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis.
  • a method of slowing progression of disease in a patient diagnosed with a chronic neurodegenerative disease comprising administering to the patient:
  • Embodiment 16 The method of Embodiment 16, in which the ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, are administered orally.
  • the neurodegenerative disease is Alzheimer's disease, Senile dementia of the Alzheimer type, Pick's disease (lobar atrophy), syndromes combining progressive dementia with other prominent neurologic abnormalities, Huntington's disease, multiple system atrophy combining dementia with ataxia and/or manifestation of Parkinson's disease, progressive supranuclear palsy (Steele- Richardson-Olszewski), diffuse Lewy body disease, corticodentatimgral degeneration, Hallervorden-Spatz disease, progressive familial myoclonic epilepsy, symptoms of gradually developing abnormalities of posture and movement, paralysis agitans (Parkinson's disease), striatonigral degeneration, progressive supranuclear palsy, torsion dystonia (torsion spasm; dystonia musculorum deformans), spasmodic torticollis and other restricted dyskinesias, Familial tremor, Gilles de la Tourette syndrome, progressive ataxi
  • composition for oral administration comprising:
  • composition of Embodiment 29, comprising ibudilast or a pharmaceutically acceptable salt thereof in an amount from about 100 mg to about 4,000 mg, divided into one, two, or three portions.
  • composition of any one of Embodiments 29-30 comprising from about 10 to 4,000 mg of GGA or a pharmaceutically acceptable salt thereof, divided into one, two, or three portions.
  • composition of any one of Embodiments 29-31 comprising from about 10 to 500 mg of riluzole or a pharmaceutically acceptable salt thereof, divided into one, two, or three portions.
  • composition of any one of Embodiments 29-32 comprising from about 100 mg to about 4,000 mg of ibudilast or a pharmaceutically acceptable salt thereof, from about 10 to 4,000 mg of GGA or a pharmaceutically acceptable salt thereof, and from about 50 mg to about 500 mg of riluzole or a pharmaceutically acceptable salt thereof.
  • composition of any one of Embodiments 29-33, wherein the ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, are in a single tablet or a single capsule dosage form.
  • composition of any one of Embodiments 29-33, wherein the ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, are in a liquid dosage form.
  • a method of treating a patient diagnosed with a neurodegenerative disease or disorder comprising administering to a patient in need thereof:
  • Embodiment 36 in which the ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, are administered orally. 38. The method of any one of Embodiments 36-37, in which the ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, are administered in a tablet or a capsule.
  • the neurodegenerative disease or disorder is Alzheimer's disease, Senile dementia of the Alzheimer type, Pick's disease (lobar atrophy), syndromes combining progressive dementia with other prominent neurologic abnormalities, Huntington's disease, multiple system atrophy combining dementia with ataxia and/or manifestation of Parkinson's disease, progressive supranuclear palsy
  • Step-Richardson-Olszewski diffuse Lewy body disease, corticodentatinigral degeneration, Hallervorden-Spatz disease, progressive familial myoclonic epilepsy, symptoms of gradually developing abnormalities of posture and movement, paralysis agitans (Parkinson's disease), striatonigral degeneration, progressive supranuclear palsy, torsion dystonia (torsion spasm; dystonia musculorum deformans), spasmodic torticollis and other restricted dyskinesias, Familial tremor, Gilles de la Tourette syndrome, progressive ataxia, cerebellar degenerations, spinocerebellar degenerations, cerebellar cortical degeneration, olivopontocerebellar atrophy (OPCA), spinocerebellar degenerations (Friedreich's ataxia and related disorders), central autonomic nervous system failure (Shy-Drager syndrome), syndromes of muscular weakness and wasting without sensory changes (motor neuron disease
  • ALS amyotrophic lateral sclerosis
  • a method of reducing a volume of an infarct (an area of necrosis in a tissue or organ resulting from obstruction of the local circulation by a thrombus or embolus) in a patient suffering from an ischemia, comprising administering to a patient in need thereof:
  • Embodiment 50 The method of Embodiment 49, in which the ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, are administered orally.
  • Embodiments 49-50 The method of any one of Embodiments 49-50, in which the ibudilast, GGA, and riluzole, or pharmaceutically acceptable salts thereof, are administered in a tablet or a capsule dosage form.
  • the neurodegenerative disease or disorder is Alzheimer's disease, Senile dementia of the Alzheimer type, Pick's disease (lobar atrophy), syndromes combining progressive dementia with other prominent neurologic abnormalities, Huntington's disease, multiple system atrophy combining dementia with ataxia and/or manifestation of Parkinson's disease, progressive supranuclear palsy (Steele-Richardson-Olszewski), diffuse Lewy body disease, corticodentatinigral degeneration, Hallervorden-Spatz disease, progressive familial myoclonic epilepsy, symptoms of gradually developing abnormalities of posture and movement, paralysis agitans (Parkinson's disease), striatonigral degeneration, progressive supranuclear palsy, torsion
  • the neurodegenerative disease or disorder is Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis.
  • a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof a therapeutically effective amount of GGA or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of riluzole or a
  • a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for alleviating negative effects of a neurodegenerative disease.
  • a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof a therapeutically effective amount of GGA or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of riluzole or a
  • a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof a therapeutically effective amount of GGA or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of riluzole or a
  • Embodiments 65-67 wherein the neurodegenerative disease or disorder is Alzheimer's disease, Senile dementia of the Alzheimer type, Pick's disease (lobar atrophy), syndromes combining progressive dementia with other prominent neurologic abnormalities, Huntington's disease, multiple system atrophy combining dementia with ataxia and/or manifestation of Parkinson's disease, progressive supranuclear palsy (Steele- Richardson-Olszewski), diffuse Lewy body disease, corticodentatinigral degeneration, Hallervorden-Spatz disease, progressive familial myoclonic epilepsy, symptoms of gradually developing abnormalities of posture and movement, paralysis agitans (Parkinson's disease), striatonigral degeneration, progressive supranuclear palsy, torsion dystonia (torsion spasm; dystonia musculorum deformans), spasmodic torticollis and other restricted dyskinesias, Familial tremor, Gilles de la Tourette syndrome, progressive
  • Embodiments 65-68 The use of any one of Embodiments 65-68, wherein the neurodegenerative disease or disorder is Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis.
  • the neurodegenerative disease or disorder is Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis.
  • Embodiments 65-69 wherein the neurodegenerative disease or disorder is ALS.
  • 71 Use of a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of GGA or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of riluzole or a
  • an infarct an area of necrosis in a tissue or organ resulting from obstruction of the local circulation by a thrombus or embolus
  • ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof.
  • ranges describing isomeric ratios disclosed herein encompass any and all possible subranges of ratios thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de manière générale des procédés permettant de traiter des maladies neurodégénératives progressives, y compris leurs formes progressives. En particulier, la présente invention concerne des procédés permettant de traiter ou de prévenir des maladies neurodégénératives progressives, y compris leurs formes progressives et leurs symptômes associés, par l'administration d'une combinaison de géranylgéranylacétone (téprénone), d'ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) et de riluzole (insérer nom chimique ?), ou de sels pharmaceutiquement acceptables de ceux-ci.
PCT/US2015/062459 2014-11-26 2015-11-24 Combinaison de géranylgéranylacétone, d'ibudilast et de riluzole, et leurs procédés d'utilisation Ceased WO2016086000A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462085159P 2014-11-26 2014-11-26
US62/085,159 2014-11-26

Publications (1)

Publication Number Publication Date
WO2016086000A1 true WO2016086000A1 (fr) 2016-06-02

Family

ID=56074980

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/062459 Ceased WO2016086000A1 (fr) 2014-11-26 2015-11-24 Combinaison de géranylgéranylacétone, d'ibudilast et de riluzole, et leurs procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2016086000A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130217718A1 (en) * 2007-07-11 2013-08-22 Medicinova, Inc. Treatment of progressive neurodegerative disease with ibudilast
US20130296323A1 (en) * 2012-02-29 2013-11-07 Coyote Pharmaceuticals, Inc. Gga and gga derivatives compositions thereof and methods for treating neurodegenerative diseases including paralysis including them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130217718A1 (en) * 2007-07-11 2013-08-22 Medicinova, Inc. Treatment of progressive neurodegerative disease with ibudilast
US20130296323A1 (en) * 2012-02-29 2013-11-07 Coyote Pharmaceuticals, Inc. Gga and gga derivatives compositions thereof and methods for treating neurodegenerative diseases including paralysis including them

Similar Documents

Publication Publication Date Title
US11278531B2 (en) Combination of ibudilast and riluzole and methods of using same
EP1696904B1 (fr) Utilisation de rotigotine pour traiter ou prevenir la perte des neurones dopaminergiques
EP1727539B1 (fr) Utilisation de rotigotine pour traiter et prevenir le syndrome parkinson plus
KR102014883B1 (ko) 근위축성 측삭 경화증 치료용 신규 조성물
Dubois et al. Chemotherapy-induced long-term alteration of executive functions and hippocampal cell proliferation: role of glucose as adjuvant
KR102014875B1 (ko) 파킨슨병을 치료하기 위한 신규의 치료적 접근법
EP1696905B1 (fr) 2-aminotetralines substituees pour le traitement prophylactique de la maladie de parkinson
JP2012528818A (ja) Ｃｍｔ及び関連障害を処置するための新たな組成物
US20230165847A1 (en) Methods of use of t-type calcium channel modulators
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
JP7296472B2 (ja) プリドピジンを使用したミトコンドリア関連疾患および障害（それらの症状を含む）の治療
CN105517546A (zh) 治疗脆性x综合征及相关疾病的方法
EP3654960A1 (fr) Utilisation d'ambroxol pour améliorer et/ou prolonger la durée de vie en bonne santé, la durée de vie et/ou l'acuité mentale
CN111936133A (zh) 药物组合物、用于该组合物的赋形剂以及该组合物的用途
US20150366847A1 (en) Combination of geranylgeranylacetone and ibudilast and methods of using same
US20210330611A1 (en) Therapy for neurological diseases/disorders
C Brett et al. Current therapeutic advances in patients and experimental models of Huntington's disease
WO2016086000A1 (fr) Combinaison de géranylgéranylacétone, d'ibudilast et de riluzole, et leurs procédés d'utilisation
Knauber et al. Modulation of striatal acetylcholine concentrations by NMDA and the competitive NMDA receptor-antagonist AP-5: an in vivo microdialysis study
CN112043700B (zh) 盐酸去亚甲基四氢小檗碱在制备预防或治疗神经退行性疾病药物中的应用
US20150320705A1 (en) Method of inhibiting or treating amyotrophic lateral sclerosis with phenoxyalkylcarboxylic acids
CN108601772A (zh) 用于治疗tdp-43蛋白质病的他克莫司
US20250235413A1 (en) Modified forms of ambroxol for therapeutic use
TW201642847A (zh) 用於靜脈內投與反丁烯二酸酯以治療神經疾病之方法及組合物
JP2025134852A (ja) 創薬のためのヒトスフェロイドの使用方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15863435

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15863435

Country of ref document: EP

Kind code of ref document: A1